SEATTLE--(BUSINESS WIRE)--KayoThera, Inc. (“KayoThera”), an early-stage therapeutics company developing novel cancer immunotherapies, today announces the closing of an $8 million Series A round of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback